Literature DB >> 29261513

High-content hydrogen water-induced downregulation of miR-136 alleviates non-alcoholic fatty liver disease by regulating Nrf2 via targeting MEG3.

Xiang Wang1, Jiao Wang1.   

Abstract

This study was aimed to investigate the potential regulatory mechanism of high-content hydrogen water (HHW) in non-alcoholic fatty liver disease (NAFLD). A high-fat diet (HFD)-induced NAFLD mice model and cellular model were prepared. The serum levels of alanine transaminase (ALT), aspartate transaminase (AST), total cholesterol (TCH) and triglycerides (TG) were measured. The expression levels of representative five microRNA (miRNAs) (miR-103, miR-488, miR-136, miR-505 and miR-148a) in liver tissues were determined by quantitative real-time PCR (qRT-PCR). The target of miR-136 was validated by RNA immunoprecipitation (RIP) and pull-down assay. MiR-136, MEG3 and nuclear factor erythroid 2-related factor 2 (Nrf2) expression levels following cell treatment were detected in hepatocytes using qRT-PCR and Western blotting. Moreover, cell viability and TG content were conducted. MiR-136 was downregulated, MEG3 as well as Nrf2 was upregulated and serum lipid level was reduced in NAFLD mice model after HHW treatment, which exerted the same effect in cellular model. RIP and RNA pull-down assay confirmed that MEG2 was a downstream target of miR-136. What's more, HHW ameliorated lipid accumulation by regulating miR-136/MEG3/Nrf2 axis in vitro and in vivo. Hence, HHW alleviated NAFLD by downregulation of miR-136 through mediating Nrf2 via targeting MEG3.

Entities:  

Keywords:  MEG3; Nrf2; high-content hydrogen water; miR-136; non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2018        PMID: 29261513     DOI: 10.1515/hsz-2017-0303

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  10 in total

Review 1.  Maternally expressed gene 3 in metabolic programming.

Authors:  Samuel Hamilton; Rafael de Cabo; Michel Bernier
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-01       Impact factor: 4.490

2.  A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease.

Authors:  Geru Tao; Guangjie Zhang; Wei Chen; Chao Yang; Yazhuo Xue; Guohua Song; Shucun Qin
Journal:  J Cell Mol Med       Date:  2022-06-23       Impact factor: 5.295

Review 3.  MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.

Authors:  Zhiqiang Fang; Guorui Dou; Lin Wang
Journal:  Int J Biol Sci       Date:  2021-04-29       Impact factor: 6.580

4.  LncRNA MEG3 up-regulates SIRT6 by ubiquitinating EZH2 and alleviates nonalcoholic fatty liver disease.

Authors:  Dongmei Zou; Liang Liu; Yinzhen Zeng; Huanhuan Wang; Dongling Dai; Mingguo Xu
Journal:  Cell Death Discov       Date:  2022-03-07

Review 5.  Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets.

Authors:  B Alipoor; S Nikouei; F Rezaeinejad; S-N Malakooti-Dehkordi; Z Sabati; H Ghasemi
Journal:  J Endocrinol Invest       Date:  2021-04-01       Impact factor: 4.256

Review 6.  Hydrogen: A Novel Option in Human Disease Treatment.

Authors:  Mengling Yang; Yinmiao Dong; Qingnan He; Ping Zhu; Quan Zhuang; Jie Shen; Xueyan Zhang; Mingyi Zhao
Journal:  Oxid Med Cell Longev       Date:  2020-09-05       Impact factor: 6.543

Review 7.  Long noncoding RNAs in lipid metabolism: literature review and conservation analysis across species.

Authors:  Kevin Muret; Colette Désert; Laetitia Lagoutte; Morgane Boutin; Florence Gondret; Tatiana Zerjal; Sandrine Lagarrigue
Journal:  BMC Genomics       Date:  2019-11-21       Impact factor: 3.969

8.  Long non‑coding RNA MEG3 knockdown alleviates hypoxia‑induced injury in rat cardiomyocytes via the miR‑325‑3p/TRPV4 axis.

Authors:  Ya Zhou; Xianguo Li; Dong Zhao; Xinya Li; Jianjun Dai
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

Review 9.  A comprehensive review of long non-coding RNAs in the pathogenesis and development of non-alcoholic fatty liver disease.

Authors:  Arezoo Gowhari Shabgah; Fatemeh Norouzi; Mahdiyeh Hedayati-Moghadam; Davood Soleimani; Naseh Pahlavani; Jamshid Gholizadeh Navashenaq
Journal:  Nutr Metab (Lond)       Date:  2021-02-23       Impact factor: 4.169

10.  MicroRNA hsa-miR-150-5p inhibits nasopharyngeal carcinogenesis by suppressing PYCR1 (pyrroline-5-carboxylate reductase 1).

Authors:  Zhiqun Li; Xiaoliu Zhou; Jiajun Huang; Zhencai Xu; Chengliang Xing; Junwei Yang; Xuejun Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.